Leap2调节β-上腺素触发的心脏反应,并引起抗高血压效应
Sixta Isabel Atencio Berrio1, Jhulle Horrane Carvalho1, João Batista Dutra1
1Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, GO, Brazil.
Life sciences
|January 31, 2026
概括
肝脏表达的抗微生物2 (LEAP2) 降低血压和心脏功能,特别是在高血压的老鼠中. 这种效应可能涉及心脏生长激素分泌受体 (GHSR) 表达的改变,这表明心脏保护潜力.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 增长激素分泌受体 (GHSR) 结合格林,但具有连接体独立的活性.
- 肝体表达的抗微生物2 (LEAP2) 是一种内源的GHSR抗剂和逆agonist.
- 了解LEAP2在心脏功能中的作用至关重要,特别是在高血压中.
研究的目的:
- 研究LEAP2对Wistar (WT) 和自发高血压大鼠 (SHR) 的心脏表现的影响.
- 探索LEAP2的心血管作用背后的机制,包括GHSR和上腺素受体的潜在参与.
主要方法:
- 在WT和SHR大鼠的体内研究.
- 孤立的老鼠心脏的ex-vivo评估.
- 在体外实验中使用隔离的心肌细胞进行实验.
- 测量动脉压,心脏内和时间.
- 对心室内压力,冠状动脉流量和细胞收缩率的分析.
- 对 ghrelin,LEAP2 和 GHSR 水平的评估.
主要成果:
- 在WT和SHR中,LEAP2注射降低了动脉压和心脏内托普主义,在SHR中效果更大.
- LEAP2在SHR中诱导了负慢性和在隔离的SHR心中降低了心室内压力.
- 在隔离的心脏和心肌细胞中,LEAP2对异二醇的反应减弱,但对乙胆的反应没有减弱.
- 在SHR心脏中发现了更高的GHSR水平,独立于循环格林和LEAP2水平.
结论:
- LEAP2显著影响心血管功能,降低血压和左心室缩性表现,特别是在高血压的情况下.
- GHSR在SHR心脏异常中的作用似乎与心脏表达的改变有关,而不是循环连接体水平.
- LEAP2与β-上腺素受体的相互作用表明它可能起到心脏保护作用.
相关概念视频
01:26Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
01:28Antihypertensive Drugs: Types of β-Blockers
1.7K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.7K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.1K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.1K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.2K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.7K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.6K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.6K